Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma

被引:137
作者
Lee, JH [1 ]
Essner, R [1 ]
Torisu-Itakura, H [1 ]
Wanek, L [1 ]
Wang, HJ [1 ]
Morton, DL [1 ]
机构
[1] John Wayne Canc Inst, Santa Monica, CA 90404 USA
关键词
D O I
10.1200/JCO.2004.01.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Approximately 20% of sentinel node (SN) positive melanoma patients have additional non-SN (NSN) metastasis. The rationale for this study was to identify the factors associated with additional nodal disease, as a method to determine which patients may most benefit from completion lymph node dissection (CLND). Patients and Methods During 1990 to 2002, 1,599 patients have undergone SN biopsy at our institute. 19.5% underwent CLND for tumor-positive SN. One hundred ninety-one of these patients had clinicopathologic information available for review. Univariate analyses used chi(2) test, Wilcoxson rank sum test, and chi(2) test for trend. Multivariate analyses used logistic regression and Wald test. Results Forty-six (24%) patients had tumor-positive NSN. Univariate analyses showed that primary thickness (Breslow and Clark), primary site, SN tumor size, and number of tumor-positive SNs were significantly associated with tumor-positive NSN. Multivariate analysis (167 patients), confirmed that Breslow and SN tumor size were independently predictive. Sex, histology, ulceration, mitotic index, and SN basin location were not predictive. Risk stratification by the number of prognostic factors present (Breslow greater than or equal to 3 mm and SN tumor size greater than or equal to 2 mm) showed that probability of finding tumor-positive NSN was 12.3% in the low-risk group (0 factors), 30.9% in the intermediate-risk group (1 factor), and 41.9% in the high-risk group (2 factors). Conclusion Thicker primary and larger SN tumor size are factors that correlate best with tumor-positive NSN. Although none of these factors are absolutely predictive of residual nodal disease, these factors must be strongly considered if the SN contains metastasis, as they provide enhanced risk assessment for NSN tumor-positivity. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:3677 / 3684
页数:8
相关论文
共 44 条
[1]  
BALCH CM, 1979, CANCER, V43, P883, DOI 10.1002/1097-0142(197903)43:3<883::AID-CNCR2820430316>3.0.CO
[2]  
2-V
[3]   Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) [J].
Balch, CM ;
Soong, SJ ;
Ross, MI ;
Urist, MM ;
Karakousis, CP ;
Temple, WJ ;
Mihm, MC ;
Barnhill, RL ;
Jewell, WR ;
Wanebo, HJ ;
Harrison, R .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :87-97
[4]   Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger [J].
Balch, CM ;
Soong, SJ ;
Bartolucci, AA ;
Urist, MM ;
Karakousis, CP ;
Smith, TJ ;
Temple, WJ ;
Ross, MI ;
Jewell, WR ;
Mihm, MC ;
Barnhill, RL ;
Wanebo, HJ .
ANNALS OF SURGERY, 1996, 224 (03) :255-263
[5]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .3. PROGNOSTIC FACTORS IN MELANOMA PATIENTS WITH LYMPH-NODE METASTASES (STAGE-II) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
INGALLS, AL ;
MADDOX, WA .
ANNALS OF SURGERY, 1981, 193 (03) :377-388
[6]   A COMPARISON OF PROGNOSTIC FACTORS AND SURGICAL RESULTS IN 1,786 PATIENTS WITH LOCALIZED (STAGE-1) MELANOMA TREATED IN ALABAMA, USA, AND NEW-SOUTH-WALES, AUSTRALIA [J].
BALCH, CM ;
SOONG, SJ ;
MILTON, GW ;
SHAW, HM ;
MCGOVERN, VJ ;
MURAD, TM ;
MCCARTHY, WH ;
MADDOX, WA .
ANNALS OF SURGERY, 1982, 196 (06) :677-684
[7]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[8]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[9]   CANCER STATISTICS, 1992 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1992, 42 (01) :19-38
[10]   Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial [J].
Cascinelli, N ;
Morabito, A ;
Santinami, M ;
MacKie, RM ;
Belli, F .
LANCET, 1998, 351 (9105) :793-796